These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 26270719)
21. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891 [TBL] [Abstract][Full Text] [Related]
22. Progress in platelet blockers: the target is the P2Y12 receptor. Patel PA; Lane B; Augoustides JG J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863 [TBL] [Abstract][Full Text] [Related]
23. Emerging P2Y12 receptor antagonists: role in coronary artery disease. Oliphant CS; Doby JB; Blade CL; Das K; Mukherjee D; Das P Curr Vasc Pharmacol; 2010 Jan; 8(1):93-101. PubMed ID: 19485932 [TBL] [Abstract][Full Text] [Related]
24. A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs. Fayaz SM; Rajanikant GK Curr Pharm Des; 2012; 18(12):1625-34. PubMed ID: 22360514 [TBL] [Abstract][Full Text] [Related]
25. Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Waite LH; Phan YL; Spinler SA Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696 [TBL] [Abstract][Full Text] [Related]
26. Current status of data on cangrelor. Qamar A; Bhatt DL Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900 [TBL] [Abstract][Full Text] [Related]
28. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
29. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Steinhubl SR; Oh JJ; Oestreich JH; Ferraris S; Charnigo R; Akers WS Thromb Res; 2008; 121(4):527-34. PubMed ID: 17631948 [TBL] [Abstract][Full Text] [Related]
30. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098 [TBL] [Abstract][Full Text] [Related]
31. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415 [TBL] [Abstract][Full Text] [Related]
32. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives. Alexopoulos D; Pappas C; Sfantou D; Lekakis J J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817 [TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538 [TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056 [TBL] [Abstract][Full Text] [Related]
35. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618 [TBL] [Abstract][Full Text] [Related]
36. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550 [TBL] [Abstract][Full Text] [Related]
37. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Bouman HJ; van Werkum JW; Rudez G; Leebeek FW; Kruit A; Hackeng CM; Ten Berg JM; de Maat MP; Ruven HJ Thromb Haemost; 2010 Feb; 103(2):379-86. PubMed ID: 20126830 [TBL] [Abstract][Full Text] [Related]
38. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB; Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867 [TBL] [Abstract][Full Text] [Related]